Dec 1 2010
Precision Therapeutics will present two abstracts at the 33rd Annual San Antonio Breast Cancer Symposium, which will be held December 8-12, 2010 in San Antonio, Texas.
Using immortalized breast cancer cell lines and the ChemoFx® Drug Response Marker, the abstract titled, "Feasibility Assessment of Pharmacogenomic Predictors Developed from Breast Cancer Cell Lines to Predict Breast Cancer Patient Pathological Response in Neoadjuvant Chemotherapy," demonstrates the feasibility of using cell-line based multi-gene predictors for predicting pathologic complete response in patients, based on their genomic profiles.
A second abstract, titled, "Pharmacogenomic Predictors of Patient Response to Chemotherapy Derived from Breast Cancer Cell Lines Combining Knowledge-Based and Data-Driven Methods," has also been selected for poster presentation at the symposium and describes a unique method for incorporating pathway enrichment analysis in developing multi-gene predictors of chemotherapeutic response, further enhancing the biological relevance of the genes identified in the predictors.
Results described in both abstracts indicate the potential utility of genomic predictors in forecasting individual patient response to chemotherapy.
"We are very pleased and honored to be presenting these two abstracts at the SABCS meeting. Having this research accepted for publication is a tremendous milestone for cancer patients as well as for the advancement of genomic research in personalized medicine," said Kui Shen, Bioinformatics Scientist at Precision Therapeutics.
Study shows AI can predict prognosis in triple-negative breast cancer